Google Translate Part 1, figure captions included but not figures, broken down into two parts due to HairLossTalk.com's 10,000 character limit.
Dr. Brotzu - Exclusive interview for Bellicapelli
Exclusive Interview with Dr. Brotzu for Bellicapelli. Here are the questions that we asked and to which he kindly responded.
1. What, in his view of the expectations that a suffering from Androgenetic Alopecia should have about your product?
2. Do you believe that this product has the potential to eliminate the problem of androgenetic alopecia?
3. Based on testing conducted by her and her opinion on the matter, which could be an average recovery potential margins and regrowth areas afffette by Androgenetic Alopecia, which are miniaturized hairs or even vellus / invisible?
4. In the case of Androgenetic Alopecia, care will have to continue "for life", or can be suspended and even terminated?
5. According to the experimentation and experience she conducted in patients suffering from Androgenetic Alopecia, which were the subjects who responded better to treatment in terms of gender / age?
6. According to the experimentation and experience she conducted in patients with Alopecia Areata, which were the subjects who responded better to treatment in terms of gender / age?
7. At present, one can predict or simply assume a very approximate date for the commercialization of the drug? What are the timelines for trials by Phidias?
8. To date, we could only see photographic documentation related Alopecia Areata.
Since statistically the number of subjects to Androgenetic Alopecia is significantly greater than that affected by Alopecia Areata, it would be possible to know if they are available and undisclosed photographic documentation for this disease? If not possible, you would know to give us a reason?
9. Given that the lotion will consist of: Diomo-gamma-linolenic acid (DGLA), carnitine, s-equol, transported within cationic liposomes, which (of course excluding their interaction) between these four components (DGLA, equol , Carnitine, cationic liposomes), in the case of Androgenetic Alopecia, believed to be the real discovery of his strength?
10. According to its experimentation and according to the documentation and experience accrued, how each component (DGLA, equol, carnitine) would act on miniaturization characteristic of androgenetic alopecia process?
11.Il preparation was effective of Androgenetic Alopecia, even without the presence of equol (which should have added later)?
12. Since the equol an anti-DHT and not having Alopecia Areata an androgenic component, considers that the equol was added because the only PGE1 (or alternatively its precursor DGLA) was not effective in cases of Androgenetic Alopecia ?
13. His experimentation done either with the use of PGE1 than with that of its precursor, ie the DGLA, showed substantial differences in results regarding Androgenetic Alopecia?
14. There have been side effects, and if so, what kind?
15. Do you believe that the product has a good chance of being marketed?
16. Believes that there are aspects and / or reasons demonstrating that the product could not be placed on the market and if so, which ones?
17. Do you think your preparation can be further enhanced / improved in the future?
18. The lotions will be different according to the type of alopecia which is hit by the patient (Androgenetic Alopecia or AA) by way of the equol component which would play action anti dht?
19. For what the product would differ from a topical classic antidht?
20. For his own experience or not, believes that in patients who have undergone a hair transplant the skin affected by grafts can benefit from its discovery by recovering indigenous hair or in this case the bulbs may have suffered excessive damage following transplantation and therefore can not be recovered?
